Complementary and alternative medicine (CAM) supplements in cancer outpatients: analyses of usage and of interaction risks with cancer treatment

被引:22
作者
Wolf, Clemens P. J. G. [1 ]
Rachow, Tobias [2 ]
Ernst, Thomas [3 ]
Hochhaus, Andreas [1 ]
Zomorodbakhsch, Bijan [4 ]
Foller, Susan [5 ]
Rengsberger, Matthias [6 ]
Hartmann, Michael [7 ]
Huebner, Jutta [8 ]
机构
[1] Univ Klinikum Jena, Klin Innere Med Hamatol & Internist Onkol 2, Klinikum 1, D-07747 Jena, Germany
[2] Univ Klinikum Jena, Klin Innere Med Hamatol & Internist Onkol 2, Pneumol, Klinikum 1, D-07747 Jena, Germany
[3] Univ Klinikum Jena, Konservat Tagesklin, Univ TumorCtr UTC, Klin Innere Med Hamatol & Internist Onkol 2, Klinikum 1, D-07747 Jena, Germany
[4] Onkol Kooperat Harz, Kosliner Str 14, D-38642 Goslar, Germany
[5] Univ Klinikum Jena, Klin Urol, Klinikum 1, D-07747 Jena, Germany
[6] Univ Klinikum Jena, Klin & Poliklin Frauenheilkunde & Fortpflanzungsm, Klinikum 1, D-07747 Jena, Germany
[7] Univ Klinikum Jena, Apotheke Univ Klinikums, Klinikum 1, D-07747 Jena, Germany
[8] Universitatsklinikum Jena, Integrat Onkol, Klin Innere Med Hamatol & Internist Onkol 2, Klinikum 1, D-07747 Jena, Germany
关键词
Drug interactions; Complementary and alternative medicine; Cancer treatment; Chemotherapy; Cancer outpatients; HUMAN CYTOCHROME-P450 3A4; GARLIC ALLIUM-SATIVUM; BREAST-CANCER; EPIGALLOCATECHIN GALLATE; POTENTIAL INTERACTIONS; DIETARY-SUPPLEMENTS; MILK THISTLE; ALOE-VERA; PHARMACOKINETICS; CHEMOTHERAPY;
D O I
10.1007/s00432-021-03675-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose The aim of our study was to analyze the use of complementary and alternative medicine (CAM) supplements, identify possible predictors, and analyze and compile potential interactions of CAM supplements with conventional cancer therapy. Methods We included outpatient cancer patients treated at a German university hospital in March or April 2020. Information was obtained from questionnaires and patient records. CAM-drug interactions were identified based on literature research for each active ingredient of the supplements consumed by the patients. Results 37.4% of a total of 115 patients consumed CAM supplements. Potential interactions with conventional cancer treatment were identified in 51.2% of these patients. All types of CAM supplements were revealed to be a potential source for interactions: vitamins, minerals, food and plant extracts, and other processed CAM substances. Younger age (< 62 years) (p = 0.020, phi c = 0.229) and duration of individual cancer history of more than 1 year (p = 0.006, phi c = 0.264) were associated with increased likelihood of CAM supplement use. A wide range of different CAM supplement interactions were reviewed: effects of antioxidants, cytochrome (CYP) interactions, and specific agonistic or antagonistic effects with cancer treatment. Conclusion The interaction risks of conventional cancer therapy with over-the-counter CAM supplements seem to be underestimated. Supplements without medical indication, as well as overdoses, should be avoided, especially in cancer patients. To increase patient safety, physicians should address the risks of interactions in physician-patient communication, document the use of CAM supplements in patient records, and check for interactions.
引用
收藏
页码:1123 / 1135
页数:13
相关论文
共 83 条
  • [81] Interactions in cancer treatment considering cancer therapy, concomitant medications, food, herbal medicine and other supplements
    Wolf, Clemens P. J. G.
    Rachow, Tobias
    Ernst, Thomas
    Hochhaus, Andreas
    Zomorodbakhsch, Bijan
    Foller, Susan
    Rengsberger, Matthias
    Hartmann, Michael
    Huebner, Jutta
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (02) : 461 - 473
  • [82] Xu Yuying, 2011, Zhongguo Zhong Yao Za Zhi, V36, P1524
  • [83] Potential interactions of complementary and alternative medicine with cancer therapy in outpatients with gynecological cancer in a comprehensive cancer center
    Zeller, T.
    Muenstedt, K.
    Stoll, C.
    Schweder, J.
    Senf, B.
    Ruckhaeberle, E.
    Becker, S.
    Serve, H.
    Huebner, J.
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (03) : 357 - 365